ABOUT
Dr. Maryna Kolochavina, PharmD, PhD, PMP. Executive leader and trusted advisor with 18 years of experience in a lifecycle asset management of over 242 rare and orphan medicinal products and advanced therapies in 42 therapeutic classes with 440 orphan drug designations, resulting in approximately $3.2bn in capital committed to alliances with biotechnology and pharmaceutical partners of all sizes. Active patient advocate for people with rare and orphan condition, representing a Patient Voice initiative in Charité, Berlin, Germany. Clinical pharmacology background with translational PhD on rare skin diseases. Member of 14 organisations, 1 board of directors